Does Medicare cover semaglutide?

The short answer depends on which semaglutide product and which indication. Medicare Part D covers Ozempic for type 2 diabetes management — that's been consistent. Wegovy coverage under Medicare is more complicated and has been shifting: the FDA's cardiovascular approval and subsequent CMS guidance opened a new pathway, but actual coverage still varies significantly by plan.

Here's how the pieces fit together.

Ozempic (diabetes indication): covered under Part D

Ozempic (semaglutide 0.5–2 mg for type 2 diabetes) is a standard Part D formulary drug. Most Medicare Part D plans cover it, though tier placement, prior authorization requirements, and cost-sharing vary. The prescription needs a documented diabetes diagnosis.

If your doctor has prescribed Ozempic for T2D and you're on Medicare, the main variables are:

• Which tier your plan places it on (typically Tier 3 or 4)
• Whether your plan requires step therapy (trying cheaper alternatives first)
• Your plan's annual deductible and cost-sharing structure

The Inflation Reduction Act's Medicare drug price negotiation provisions are bringing negotiated pricing to more high-cost drugs over time; semaglutide may be subject to negotiated pricing as the program expands.

Wegovy (weight-loss indication): the coverage evolution

For years, Medicare was legally prohibited from covering drugs prescribed primarily for weight loss. This was a decades-old statutory provision, not a policy preference. Wegovy (semaglutide 2.4 mg for obesity) launched in 2021 and was mostly inaccessible to Medicare beneficiaries as a result.

The SELECT trial changed the calculus. When the FDA approved Wegovy for reducing cardiovascular risk in people with established cardiovascular disease and obesity in March 2024, it created a new category: a drug approved for a cardiovascular indication, not solely for weight loss.

CMS subsequently clarified that Medicare Part D plans may cover anti-obesity medications when prescribed for a cardiovascular risk-reduction indication — removing the prior restriction, at least for that indication. This is the relevant shift for Medicare beneficiaries with established heart disease (prior MI, stroke, or peripheral artery disease) who are overweight or obese.

What "may cover" means in practice

The CMS guidance opened coverage as an option, not a mandate. Whether any specific Medicare Part D plan covers Wegovy depends on:

• Plan formulary decisions — each Part D plan sets its own formulary within CMS rules; some added Wegovy for the CV indication, others haven't
• Prior authorization criteria — plans typically require documentation of the cardiovascular diagnosis, BMI ≥ 27, and often a prescriber attestation that the indication is cardiovascular risk reduction
• Step therapy — some plans may require trying lifestyle interventions or other medications first
• Tier placement — specialty tier placement means higher cost-sharing even when covered

The practical result is significant variation. A beneficiary on one Part D plan may have Wegovy covered at $35–$100/month after meeting deductibles, while a beneficiary on a different plan has no coverage at all.

How to find out if your plan covers it

1. Check your plan's formulary — Part D plans publish formularies on Medicare.gov and their own websites; search for "semaglutide" or "Wegovy"
2. Call your plan's member services — ask specifically about coverage under the cardiovascular indication with the relevant diagnosis codes
3. Talk to your prescriber — prescribers are often aware of which plans in their patient population are covering Wegovy and what documentation is needed for prior auth
4. Check the Medicare Plan Finder — during open enrollment, you can filter by drug coverage for specific medications

Coverage rules under Medicare change annually with plan formulary updates. If your plan doesn't cover Wegovy today, it's worth checking again at open enrollment (October 15 – December 7 each year).

Medicare Advantage plans

Medicare Advantage (Part C) plans follow different formulary rules than standalone Part D. Some Advantage plans have added Wegovy coverage more broadly — including for the obesity indication beyond the cardiovascular pathway — as a benefit differentiator. Coverage availability in Medicare Advantage is even more variable than in standalone Part D.

What about cost without coverage?

Without coverage, Wegovy retail price is around $1,300–$1,400/month as of 2025. Manufacturer savings programs (Novo Nordisk's savings card) are typically not available to Medicare beneficiaries — federal anti-kickback rules generally prohibit drug manufacturers from providing cost-sharing assistance for Medicare-covered (or Medicare-eligible) products. This is a meaningful gap.

Generic semaglutide isn't commercially available under Medicare in the same way as brand-name products; compounded semaglutide access has contracted since the FDA removed semaglutide from the drug shortage list.

Related questions

• What's the cheapest way to get semaglutide?
• Generic semaglutide in 2026?
• The SELECT trial explained
• Semaglutide guide — the full picture on Ozempic and Wegovy